REPH
Recro Pharma, Inc.
Set alert
2.09 0.00 0.00%
2.00 Day range 2.14
52-week range unavailable
- Open
- 2.07
- Prev close
- 2.09
- Mkt cap
- 123.23M
- Vol
- 137.54K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.00
- High
- 2.14
- Forward P/E
- -11.61
- Beta
- 0.00
- Short ratio
- 5.87
- Inst. own
- 54.96%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 5, 2022
- 50-d avg
- 1.73
- 200-d avg
- 1.88
- 1y target
- 5.00
Key statistics
- Market cap
- 123.23M
- Enterprise value
- 171.67M
- Trailing P/E
- 0.00
- Forward P/E
- -11.61
- PEG ratio
- -0.61
- Price / sales
- 1.64
- Price / book
- 2.32
- EPS (TTM)
- -0.26
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -15.09%
- Revenue (TTM)
- 75.36M
- Revenue growth
- 125.00%
- Free cash flow
- -468.25K
- Total cash
- 25.22M
- Total debt
- 103.52M
- Return on equity
- -81.32%
- Shares outstanding
- 56.42M
- Short % of float
- 1.26%
- 50-day average
- 1.73
- 200-day average
- 1.88
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 5.00 +139.2% upside
Now 2.09
- Target (low)
- 4.00
- Target (mean)
- 5.00
- Target (high)
- 6.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy1
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
May 5, 2022
Expected May 5, 2022. Consensus EPS estimate -0.09.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 5, 2022 | Mar 1, 2022 | -0.04 | — | — | — |
| Mar 1, 2022 | Dec 1, 2021 | -0.07 | — | — | — |
| Nov 9, 2021 | Sep 1, 2021 | -0.05 | — | — | — |
| Aug 9, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 6, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Feb 26, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2021 | William Blair | init | — | Outperform |
| May 12, 2020 | Oppenheimer | main | — | Outperform |
| Mar 5, 2020 | Stephens & Co. | main | — | Overweight |
| Nov 26, 2019 | Stephens & Co. | main | — | Overweight |
| Oct 17, 2019 | Stephens & Co. | init | — | Overweight |
| Mar 25, 2019 | Roth Capital | down | Buy | Neutral |
About Recro Pharma, Inc.
Recro Pharma, Inc., a contract development and manufacturing organization, engages in the development, manufacturing, and packaging for various therapeutic dosage forms primarily in the small molecule therapeutic development in the United States and internationally. It offers its products in the form of oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder filled capsules, ophthalmic droppers, liposomes, and nano/microparticles, as well as in the areas of aseptic fill/finish, lyophilization, packaging, and logistics services. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was incorporated in 2007 and is based in Exton, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- recrocdmo.com
News
- Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
- Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
- Recro to Present at H.C. Wainwright BioConnect 2022 Conference
- Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
- Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
- Earnings Scheduled For November 9, 2021
- Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
- Recro Reports Inducement Grants For New Staff
- Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
- Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Your note
Sign in to keep a note on REPH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ASHTON WILLIAM L | Director | Stock Award(Grant) | Apr 19, 2021 | 80,280 |
| AWM INVESTMENT COMPANY, INC. | Beneficial Owner of more than 10% of a Class of Security | Sale | Dec 20, 2021 | 0 |
| BERELOWITZ MICHAEL | Director | Stock Award(Grant) | Apr 19, 2021 | 76,546 |
| CHURCHILL WINSTON J. JR. | Director | Stock Award(Grant) | Apr 19, 2021 | 77,982 |
| ENLOE J DAVID JR | Chief Executive Officer | Purchase | Mar 14, 2022 | 524,879 |
| HENWOOD GERALDINE A | Director | Stock Award(Grant) | Apr 19, 2021 | 276,574 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AWM Investment Company, Inc. | 9.01% | 5,081,901 | 8.69M | Dec 30, 2021 |
| Cowen Prime Advisors LLC | 7.45% | 4,204,000 | 7.19M | Dec 30, 2021 |
| Samjo Capital LLC | 5.67% | 3,200,000 | 5.47M | Dec 30, 2021 |
| Athyrium Capital Management, LP | 3.90% | 2,202,420 | 3.77M | Dec 30, 2021 |
| Alyeska Investment Group, L.P. | 3.18% | 1,796,720 | 3.07M | Dec 30, 2021 |
| Vanguard Group, Inc. (The) | 3.00% | 1,694,462 | 2.90M | Dec 30, 2021 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.00% | 1,130,309 | 1.93M | Dec 30, 2021 |
| Buffalo Early Stage Growth Fund | 1.22% | 690,000 | 1.18M | Dec 30, 2021 |
| Vanguard Extended Market Index Fund | 0.84% | 472,521 | 808.01K | Dec 30, 2021 |
| First Eagle Small Opportunity Fund | 0.38% | 214,775 | 418.81K | Oct 30, 2021 |
| Fidelity Extended Market Index Fund | 0.38% | 213,994 | 365.93K | Dec 30, 2021 |
| Russell Inv Co-U.S. Small Cap Equity Fund | 0.24% | 136,069 | 265.33K | Oct 30, 2021 |